Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.38 |
| ▸ | ACACA | Q13085 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | EBP | Q15125 | 3/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.32 |
| ▸ | TOP2A | P11388 | 4/20 | 0.31 |
| ▸ | TOP2B | Q02880 | 4/20 | 0.31 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.31 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.31 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL159792 | 0.88 | EBP (0.47) | ACLYACACAHSD11B1PTPN11EBP | |
| SCHEMBL464758 | 0.87 | HSD11B1 (0.49) | ACLYACACAHSD11B1PTGS1PTGS2 | |
| SCHEMBL6341662 | 0.83 | HSD11B1 (0.45) | ACLYACACAHSD11B1PTGS1PTGS2 | |
| SCHEMBL10635071 | 0.77 | HSD11B1 (0.40) | ACLYACACAHSD11B1PTGS1PTGS2 | |
| Niacin SCHEMBL6684757 | 0.76 | EBP (0.39) | ACLYACACAHSD11B1PTGS1PTGS2 | |
| SCHEMBL1874653 | 0.74 | ACLY (0.48) | ACLYACACAHSD11B1EP300PTGS1 | |
| SCHEMBL2257958 | 0.73 | EBP (0.45) | ACLYACACAHSD11B1EBPPRKAG1 | |
| SCHEMBL12634185 | 0.72 | ACLY (0.67) | ACLYACACAHSD11B1EP300PTGS1 | |
| SCHEMBL29510985 | 0.72 | ACLY (0.67) | ACLYACACAHSD11B1EP300PTGS1 | |
| SCHEMBL10349517 | 0.70 | EBP (0.39) | ACLYACACAHSD11B1PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3236310-A | — | — | None | — | — | JP | disclosed |
| EP-2377874-B1 | Compositions comprising a lophenol | MORINAGA MILK INDUSTRY CO LTD (JP) | 2019-01-23 | — | — | EP | disclosed |
| US-9592264-B2 | Delivery system for saw palmetto extract and carotenoid | U.S. Nutraceuticals, LLC (US) | 2017-03-14 | — | — | US | disclosed |
| US-20140302136-A1 | DELIVERY SYSTEM FOR SAW PALMETTO EXTRACT AND CAROTENOID | U.S. NUTRACEUTICALS, LLC D/B/A VALENSA INTERNATIONAL (US) | 2014-10-09 | — | — | US | disclosed |
| WO-2014165561-A2 | DELIVERY SYSTEM FOR SAW PALMETTO EXTRACT AND CAROTENOID | U.S. NUTRACEUTICALS, LLC D/B/A VALENSA INTERNATIONAL (US) | 2014-10-09 | — | — | WO | disclosed |
| US-8470807-B2 | Antioxidant | MORINAGA MILK INDUSTRY CO., LTD. (JP) | 2013-06-25 | — | — | US | disclosed |
| EP-1343860-B1 | A PROCESS FOR PREPARING VEGETABLE OIL FRACTIONS RICH IN NON-TOCOLIC, HIGH-MELTING, UNSAPONIFIABLE MATTER | AARHUSKARLSHAMN DENMARK AS (DK) | 2012-01-25 | — | — | EP | disclosed |
| EP-2377874-A1 | ANTIOXIDANT | Morinaga Milk Industry Co., Ltd. (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-20110212931-A1 | ANTIOXIDANT | MORINAGA MILK INDUSTRY CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| CN-101098702-B | Drugs, food or drink for improving pancreatic functions | MORINAGA MILK INDUSTRY CO LTD | 2010-12-29 | — | — | CN | disclosed |
| WO-2002050221-A1 | A PROCESS FOR PREPARING VEGETABLE OIL FRACTIONS RICH IN NON-TOCOLIC, HIGH-MELTING, UNSAPONIFIABLE MATTER | AARHUS OLIEFABRIK A/S (DK) | 2002-06-27 | — | — | WO | disclosed |
| EP-1146798-A2 | MODIFIED FOOD PRODUCTS AND BEVERAGES, AND ADDITIVES FOR FOOD AND BEVERAGES | Nutrahealth Ltd. (UK) (GB) | 2001-10-24 | — | — | EP | disclosed |
| US-20010008638-A1 | NUTRITIONAL SUPPLEMENT COMPRISING AT LEAST ONE PROHORMONE AND AT LEAST ONE ANTI-ESTROGEN COMPOUND IN A TIME-RELEASE DOSAGE FORM | KAIZEN, INC. | 2001-07-19 | — | — | US | disclosed |
| WO-2001039656-A2 | METHOD OF MEDICAL MANAGEMENT FOR LOWER URINARY TRACT SYMPTOMS AND BENIGN PROSTATIC HYPERPLASIA | STARCOR PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| US-6200573-B1 | Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia | STARCOR PHARMACEUTICALS, INC. | 2001-03-13 | — | — | US | disclosed |
| WO-2000041491-A2 | MODIFIED FOOD PRODUCTS AND BEVERAGES, AND ADDITIVES FOR FOOD AND BEVERAGES | NUTRAHEALTH LTD (UK) (GB) | 2000-07-20 | — | — | WO | disclosed |
| US-5972345-A | COMPRISING SAW PALMETTO EXTRACT, AFRICAN PYGEUM EXTRACT, STINGING NETTLE EXTRACT | CHIZICK STEPHEN (CA) | 1999-10-26 | — | — | US | disclosed |
| EP-0914329-A2 | METHOD OF MANUFACTURING AN ESTER MIXTURE | UNILEVER N.V. (NL) | 1999-05-12 | — | — | EP | disclosed |
| WO-1998001126-A2 | METHOD OF MANUFACTURING A STEROL ESTER MIXTURE | UNILEVER N.V. (NL) | 1998-01-15 | — | — | WO | disclosed |
| JP-H03236310-A | HAIR TONIC | NONOGAWA SHOJI:KK | 1991-10-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212931-A1 | ANTIOXIDANT | GPX4, GPX1, LPO | ACLY 2017/4885ACACA 382/4885HSD11B1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.